99 related articles for article (PubMed ID: 27449101)
1. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
[TBL] [Abstract][Full Text] [Related]
2. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.
Sonobe R; Yang P; Suzuki MM; Shinjo K; Iijima K; Nishiyama N; Miyata K; Kataoka K; Kajiyama H; Kondo Y
Cancer Sci; 2024 Jun; 115(6):1910-1923. PubMed ID: 38558246
[TBL] [Abstract][Full Text] [Related]
5. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M; Bartosch C; Abreu MH; Richardson A; Almeida R; Ricardo S
Cells; 2024 May; 13(9):. PubMed ID: 38727322
[TBL] [Abstract][Full Text] [Related]
7. Hsa_circ_0006260 Mediates Trophoblast Function by Fibronectin Type III Domains Containing Protein 5 via Interacting with miR-770-5p.
Liu W; Hu XC; Huang H; He MT
Biochem Genet; 2024 Apr; ():. PubMed ID: 38642175
[TBL] [Abstract][Full Text] [Related]
8. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA from Tyrosylprotein Sulfotransferase 2 Gene Inhibits Cisplatin Sensitivity in Head and Neck Squamous Cell Carcinoma by Sponging miR-770-5p and Interacting with Nucleolin.
Wang T; Xin C; Zhang S; Tian X; Hu Y; Wang Y; Wang J; Ji N; Zeng X; Li J
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001611
[TBL] [Abstract][Full Text] [Related]
10. Investigation of XPD, miR-145 and miR-770 expression in patients with end-stage renal disease.
Citak E; Yalin SF; Altiparmak MR; Guven M
Mol Biol Rep; 2023 Aug; 50(8):6843-6850. PubMed ID: 37392287
[TBL] [Abstract][Full Text] [Related]
11. KIAA1549 promotes the development and chemoresistance of colorectal cancer by upregulating ERCC2.
Ye F; Xie Y; Lin M; Liu Y; Fang Y; Chen K; Zhang Y; Ding Y
Mol Cell Biochem; 2024 Mar; 479(3):629-642. PubMed ID: 37140813
[TBL] [Abstract][Full Text] [Related]
12. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A; Cainap SS; Havasi AT; Cainap C
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
[TBL] [Abstract][Full Text] [Related]
13. Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment.
Cui M; Liu Y; Cheng L; Li T; Deng Y; Liu D
Front Immunol; 2022; 13():1050917. PubMed ID: 36439168
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicles and Resistance to Anticancer Drugs: A Tumor Skeleton Key for Unhinging Chemotherapies.
Pompili S; Vetuschi A; Sferra R; Cappariello A
Front Oncol; 2022; 12():933675. PubMed ID: 35814444
[TBL] [Abstract][Full Text] [Related]
15. Let-7a mimic transfection reduces chemotherapy-induced damage in a mouse ovarian transplantation model.
Alexandri C; Van Den Steen G; Demeestere I
Sci Rep; 2022 Jun; 12(1):10863. PubMed ID: 35760952
[TBL] [Abstract][Full Text] [Related]
16. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.
Schwarzenbach H; Gahan PB
Cancer Drug Resist; 2019; 2(2):271-296. PubMed ID: 35582723
[TBL] [Abstract][Full Text] [Related]
17. Collagen-based three-dimensional culture microenvironment promotes epithelial to mesenchymal transition and drug resistance of human ovarian cancer
Liu M; Zhang X; Long C; Xu H; Cheng X; Chang J; Zhang C; Zhang C; Wang X
RSC Adv; 2018 Feb; 8(16):8910-8919. PubMed ID: 35539845
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA as a Potential Therapeutic Molecule in Cancer.
Szczepanek J; Skorupa M; Tretyn A
Cells; 2022 Mar; 11(6):. PubMed ID: 35326459
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
